Scarica l'app Stockscreener
96.39
0.30%
-0.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$96.81
Aprire:
$96.5
Volume 24 ore:
3.24M
Relative Volume:
0.27
Capitalizzazione di mercato:
$167.49B
Reddito:
$45.13B
Utile/perdita netta:
$6.28B
Rapporto P/E:
26.85
EPS:
3.5895
Flusso di cassa netto:
$7.40B
1 W Prestazione:
-4.14%
1M Prestazione:
-8.47%
6M Prestazione:
-25.47%
1 anno Prestazione:
-26.31%
Intervallo 1D:
$95.80
$97.32
Intervallo di 1 settimana:
$93.92
$102.48
Portata 52W:
$93.92
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Nome
Abbott Laboratories
Settore
Industria
Telefono
(224) 667-6100
Indirizzo
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
96.39 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
339.74 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.05 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.31 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.60 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-10 | Iniziato | The Benchmark Company | Buy |
| 2025-07-18 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-06-16 | Iniziato | Leerink Partners | Market Perform |
| 2024-10-08 | Iniziato | Oppenheimer | Outperform |
| 2024-09-19 | Iniziato | Piper Sandler | Overweight |
| 2024-07-30 | Downgrade | Edward Jones | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2023-07-21 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Reiterato | Barclays | Overweight |
| 2023-04-20 | Reiterato | Bernstein | Outperform |
| 2023-04-20 | Reiterato | JP Morgan | Overweight |
| 2023-04-20 | Reiterato | Raymond James | Outperform |
| 2023-04-20 | Reiterato | UBS | Buy |
| 2023-04-20 | Reiterato | Wolfe Research | Underperform |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2022-10-26 | Iniziato | Mizuho | Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-27 | Reiterato | Credit Suisse | Outperform |
| 2022-01-27 | Reiterato | Morgan Stanley | Overweight |
| 2022-01-27 | Reiterato | Raymond James | Outperform |
| 2022-01-27 | Reiterato | UBS | Buy |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-10-27 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Iniziato | Redburn | Neutral |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Neutral |
| 2021-01-28 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Outperform |
| 2020-06-01 | Downgrade | Goldman | Neutral → Sell |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Neutral |
| 2020-02-06 | Ripresa | BTIG Research | Neutral |
| 2020-01-02 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-06-13 | Reiterato | BofA/Merrill | Buy |
| 2019-02-07 | Reiterato | BofA/Merrill | Buy |
| 2019-01-02 | Downgrade | Citigroup | Neutral → Sell |
| 2018-11-30 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-06-27 | Iniziato | Bernstein | Outperform |
| 2018-01-30 | Reiterato | Citigroup | Neutral |
| 2018-01-25 | Reiterato | Stifel | Buy |
| 2018-01-25 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-10-19 | Reiterato | Stifel | Buy |
Mostra tutto
Abbott Laboratories Borsa (ABT) Ultime notizie
Abbott Laboratories stock (US0028241000): Why Google Discover changes matter more now - AD HOC NEWS
Bernstein SocGen cuts Abbott Labs stock price target on weak quarter - Investing.com Canada
Has the Abbott Laboratories Sell-Off Finally Created an Entry Point? - 24/7 Wall St.
Abbott price target lowered to $143 from $144 at Barclays - TipRanks
Market Crash: 2 Healthcare Stocks Worth Loading Up on at a Discount - The Motley Fool
Intuitive Surgical (ISRG) Q1 Earnings: What To Expect - TradingView
Abbott Laboratories stock (US0028241000): Is diagnostics strength enough to drive sustained growth f - AD HOC NEWS
Abbott Laboratories in charts: Medical Devices continues to see Y/Y double-digit growth momentum in Q1; nutrition falls - MSN
Notable healthcare headlines for the week: J&J, Abbott and Organon in focus - MSN
Assessing Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
ABT: Abbott Laboratories Lowers Earnings Outlook Despite Revenue Beat - GuruFocus
How Abbott is Changing the Way We Treat AFib - Tomorrow's World Today
Abbott Laboratories (ABT) Margin Drop To 13.9% Challenges Bullish Earnings Narratives - simplywall.st
Ninety One UK Ltd Acquires New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Ninety One North America Inc. - MarketBeat
Abbott Laboratories $ABT Shares Sold by Lbp Am Sa - MarketBeat
Abbott Laboratories stock (US0028241000): Why diagnostics strength is suddenly worth a closer look - AD HOC NEWS
Abbott Laboratories (NYSE:ABT) Short Interest Up 19.4% in March - MarketBeat
Abbott Reaches Preliminary Settlement in Derivative Governance Case - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
[8-K] ABBOTT LABORATORIES Reports Material Event - Stock Titan
ABT Maintained by Piper Sandler -- Price Target Lowered to $115 - GuruFocus
Abbott Labs Stock (ABT) Hit with Slew of Downgrades After Earnings - TipRanks
Abbott Laboratories cuts outlook, says mild flu season hurt sales - MSN
China Diabetes Devices Market Forecast and Company Analysis Report 2026-2034 Featuring Roche, Abbott Laboratories, Novo Nordisk, BD, Medtronic, Eli Lilly, and Sanofi - Yahoo Finance
Abbott Laboratories Sales Growth Outlook 'Leaves Room For Upside': Analyst - Benzinga
Abbott stock crash: Rebound could be coming fast - MSN
Piper Sandler cuts Abbott Labs stock price target on weak diabetes sales - Investing.com
Abbott Stock Crash: Rebound Could Be Coming Fast - MarketBeat
TD Cowen lowers Abbott stock price target to $115 on guidance cut - Investing.com
ABT Maintained by Evercore ISI Group -- Price Target Lowered to $120 - GuruFocus
RBC Capital lowers Abbott Labs stock price target on Q1 results - Investing.com Australia
Abbott Labs’ Financial Results Narrowly Beat Forecasts - Baystreet.ca
A Quick Look at Today's Ratings for Abbott Laboratories(ABT.US), With a Forecast Between $115 to $144 - Moomoo
Abbott Laboratories (NYSE:ABT) Price Target Cut to $110.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Bernstein SocGen cuts Abbott Labs stock price target on growth concerns - Investing.com Canada
Citigroup Lowers Abbott Laboratories (NYSE:ABT) Price Target to $108.00 - MarketBeat
Wells Fargo Adjusts Price Target on Abbott Laboratories to $109 From $122, Maintains Overweight Rating - Moomoo
Oppenheimer Adjusts Price Target on Abbott Laboratories to $115 From $132, Maintains Outperform Rating - marketscreener.com
Abbott (ABT) Stock Price Prediction 2027: Analyst Targets, Q1 2026 Earnings & Bull/Bear Scenarios - techi.com
Abbott lowers EPS guidance on Exact Sciences buy as shares slide - Fierce Biotech
Citigroup Cuts Price Target on Abbott Laboratories to $108 From $136, Maintains Buy Rating - marketscreener.com
Benchmark Adjusts Price Target on Abbott Laboratories to $120 From $145, Maintains Buy Rating - marketscreener.com
JPMorgan Adjusts Price Target on Abbott Laboratories to $110 From $123, Maintains Overweight Rating - marketscreener.com
Benchmark cuts Abbott Labs stock price target on valuation to $120 - Investing.com
Oppenheimer cuts Abbott stock price target to $115 on guidance - Investing.com
Abbott Laboratories (NYSE:ABT) Q1 2026 Earnings Call Transcript - Insider Monkey
Why Is Abbott Stock Trending Lower? - Trefis
Abbott Price Prediction: Where Will the Stock Be in 2027 - 24/7 Wall St.
Why Abbott Laboratories stock tumbled on Thursday - MSN
Abbott Laboratories Stock Tumbles 6% On Weak Q2 Earnings Guidance - TIKR.com
Abbott Laboratories Azioni (ABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):